10 Cheap Biotech Stocks That Could Soar
Celldex Therapeutics (CLDX)
Small phase II studies have shown promising efficacy from Celldex's cancer immunotherapy "vaccine" CDX-110 in patients with glioblastoma, an aggressive form of brain cancer. What's needed next is a large, well-designed phase III study of CDX-110 in patients with glioblastoma that can more conclusively demonstrate the drug's ability to help patients live longer.
And therein lies the risk in Celldex. Pfizer (PFE) gave up on Celldex and CDX-110, returning rights to the drug and forcing the company to design and fund a phase III study on its own. This study is expected to begin later this year but the wait for data will be long. Also pay attention to Celldex's second pipeline drug, CDX-011, which is being tested in a 120-patient, randomized, controlled phase IIb clinical trial in advanced breast cancer. (The study will enroll a large number of women with so-called "triple negative" disease, which is very difficult to treat.) Celldex expects enrollment to be complete by the end of the year, which should yield results in 2012.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
